Semaglutide 2.4 mg may significantly improve liver fibrosis and resolve MASH in ESSENCE trial Dr. Kamal Kant Kohli5 Nov 2024 9:30 AM ISTAccording to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver fibrosis and...
CDSCO Panel grants Novo Nordisk Protocol Amendment Proposal to study concizumab Dr. Divya Colin27 Oct 2024 5:00 PM ISTNew Delhi: Recommending to increase the number of subjects from 15 to 35, the Subject Expert Committee (SEC) functional under the Central Drug...
West Pharma Raises 2024 Profit Forecast Amid Surging Demand for Injectable Therapy Supplies MD Bureau27 Oct 2024 9:45 AM ISTBengaluru: West Pharmaceutical Services raised its annual profit outlook on Thursday after exceeding Wall Street's expectations for quarterly...
Roche seeks to block Novo Nordisk's Catalent deal over weight-loss drug competition MD Bureau24 Oct 2024 2:09 PM IST"Limiting the competition in this space is not a good idea," Thomas Schinecker, CEO, Roche said.
Novo Nordisk's oral Semaglutide cuts cardiovascular risks by 14 percent, study finds MD Bureau23 Oct 2024 3:29 PM ISTNovo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.
Oral semaglutide cuts MACE risk by 14% in adults with type 2 diabetes: SOUL trial Dr. Kamal Kant Kohli22 Oct 2024 9:30 AM ISTAccording to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will present more detailed...
Block Novo Holdings' USD16.5B Catalent acquisition: Consumer Groups Urge FTC over antitrust concerns MD Bureau19 Oct 2024 11:30 AM ISTThe deal could constrain options for competitors such as Amgen, Pfizer, Roche, and AstraZeneca , who are reportedly developing their own GLP 1 drugs.
Natco Pharma partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US Ruchika Sharma7 Oct 2024 12:30 PM ISTHyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S....
Monlunabant found effective for weight loss obesity and metabolic syndrome in phase 2a trial Dr. Kamal Kant Kohli5 Oct 2024 8:30 AM ISTNovo Nordisk today announced that in a phase 2a trial, monlunabant, a novel oral cannabinoid receptor 1 inverse agonist, was associated with weight...
Medical Bulletin 12/ September/ 2024 Dr. Garima Soni12 Sept 2024 3:00 PM ISTHere are Top Medical News of the Day:Gene Therapy Improves Vision in hereditary blindness: Study FindsBothnia dystrophy is a form of hereditary...
13% Weight Loss Achieved Over Three Months With Amycretin: Phase 1 Trial Finds Dr. Garima Soni12 Sept 2024 8:45 AM ISTIndividuals who received a once-a-day oral weight loss drug lost up to 13% of their body weight over three months, new research was presented at the...
Catalent beats revenue estimates ahead of deal close with Novo Holdings MD Bureau Team1 Sept 2024 1:30 PM ISTBengaluru: Contract drug manufacturer Catalent beat analysts' estimates for fourth-quarter revenue on Thursday, helped by its biologics segment...
